Press Releases

Media Coverage

Bolt Bio Adds $93.5M to Move Ahead Immune-Stimulating Cancer Drugs

Xconomy

Piramal Pharma Solutions and Bolt Biotherapeutics Sign Production Agreement

ADC Review

U.S. Patent for Bolt Biotherapeutics’ Boltbody™ ISAC Platform Technology is a Major Milestone in the Development of BDC-1001

ADC Review

Randall Schatzman, Ph.D. to Lead Growth of Immune- Stimulating Antibody Conjugates at Bolt Biotherapeutics

ADC Review

How the Next Generation Antibody Drug Conjugates Expands Beyond Cytotoxic Payloads for Cancer Therapy

ADC Review

Bolt Biotherapeutics Nabs $93.5M to Push Provenge Inventor’s New Idea Deeper in the Clinic

Endpoints News

Bolt’s Myeloid Twist on ADCs Charged up with $93.5M series C

BioCentury

Pfizer-Backed Bolt Therapeutics Strikes $93.5M Funding Round As Lead Med Hits the Clinic

Fierce Biotech

Agonist ecstasy? HER2 (and more) ‘Bolt’-on strategy draws $93.5M series C

BioWorld

Bolt Biotherapeutics Initiates Immunotherapy Trial of Lead Drug Candidate in HER2-Expressing Solid Tumors

Precision Oncology News

Podcasts

Dr. Randy Schatzman On Dodging Disruption: The New Fundraising Norm

Business of Biotech Podcast

Listen Now

CMC Considerations For In-Human Studies with Drs. Edith Perez and Nathan Ihle

Business of Biotech Podcast

Listen Now

Randy Schatzman, PhD, CEO of Bolt Biotherapeutics

Biotech 2050 Podcast

Listen Now

Advances in Targeted Cancer Therapy
with Dr. Edith Perez

Empowered Patient Podcast

Listen Now

Posters & Publications

Immune-stimulating antibody conjugates elicit robust myeloid activation and durable antitumor immunity

Ackerman SE, et al., Nature Cancer (2020)

View Now

Phase 1/2 study of novel HER2-targeting, TLR7/8 immune-stimulating antibody conjugate (ISAC) BDC-1001 as a single agent and in combination with an immune checkpoint inhibitor in patients with advanced HER2-expressing solid tumors

Presented at: 2020 San Antonio Breast Cancer Symposium

View Now

Phase 1/2 study of novel HER2-targeting, TLR7/8 immune-stimulating antibody conjugate (ISAC) BDC-1001 with or without immune checkpoint inhibitor in patients with advanced HER2-expressing solid tumors

Presented at: 2020 Society for Immunotherapy of Cancer (SITC)

View Now

Covalent attachment of a TLR7/8 agonist to tumor-targeting antibodies drives potent anti-tumor efficacy by synergistically activating FcγR- and TLR- signaling and enables safe systemic administration

Presented at: 2020 Society for Immunotherapy of Cancer (SITC)

View Now

Systemically administered HER2-targeted ISACs provoke a rapid, local response that engages the innate and adaptive arms of the immune system to eradicate tumors in preclinical models

Presented at: 2020 Society for Immunotherapy of Cancer (SITC)

View Now

HER2-targeting TLR 7/8 immune-stimulating antibody conjugates elicit robust myeloid activation and anti-tumor immune responses in a TLR- and FcR-dependent manner

Presented at: 2019 Society for Immunotherapy of Cancer (SITC)

View Now

TLR7/8 immune stimulating antibody conjugates elicit robust myeloid activation and durable anti-tumor immunity

Presented at: 2019 American Association for Cancer Research (AACR)

View Now

Systemic Immunity is Required for Effective Cancer Immunotherapy

Spitzer MH, et al. Cell (2017)

View Now

Allogenic IgG Combined with Dendritic Cell Stimuli Induce Antitumor T-cell Immunity

Carmi Y, et al. Nature (2015)

View Now